Reading Litigation Disclosures for Threats to Exclusivity

Picture the usual reading session. The annual report is open to Item 3, Legal Proceedings, and the section runs four pages. There's a product-liability suit, a shareholder class action, a dispute with a former distributor, and somewhere in the middle, written in the same flat tone as everything else, a paragraph saying that two generic drugmakers have filed applications with the FDA and that the company has sued them for patent infringement. Most readers skim it. The prose is built to be skimmed.

The structural question that paragraph raises is simple, though: if the company loses this case, does anything still keep a competitor from selling the same thing? For a business whose advantage is a patent, a license or a protected brand, the answer can be no. And a legal proceedings section treats a lawsuit that could remove the whole moat exactly the way it treats a slip-and-fall claim. Same font. Same hedged language. Same position in the filing.

So reading litigation disclosures for moat analysis is mostly a sorting exercise. The goal isn't to predict who wins in court; I can't do that, and I'd distrust anyone who says they can from a 10-K. It's to separate the suits that are background noise from the ones aimed at the load-bearing piece of the business. Below are five things to read for, followed by a case where all five showed up in the filings well before the revenue line caught up.

Routine Litigation Versus a Challenge to the Wall Itself

Large companies are sued constantly. A consumer brand enforces its trademarks against counterfeiters every year. A technology company defends dozens of suits from patent-assertion entities that make nothing and license everything. A medical-device maker trades infringement claims with its two closest rivals as a matter of habit. None of this, by itself, says much about the moat. It's the cost of owning something worth copying.

What changes the picture is the target. Litigation matters for competitive position when three things are true at once: the asset under attack is the one carrying the economics, the challenger wants to sell a substitute rather than collect a royalty, and a loss would remove the barrier rather than just make it more expensive to maintain. I covered the general case for patents, brands and licenses as moat sources in our piece on intangible assets as moats. The litigation section is where you find out whether those intangibles are being tested.

The sorting test: Is this the asset that carries the profits? Does the other side want to sell a substitute? Would losing remove the barrier, or only raise its cost? Three yeses means the suit is about the moat.

Five Things the Litigation Disclosures Will Tell You

Each of these lives in a slightly different part of the filing. Item 3 (Legal Proceedings) and the commitments-and-contingencies footnote carry most of it, but the business description and the risk factors fill in what the legal sections leave out, including which patents cover which products and when they expire.

1. Who is suing, and what they want to sell

A suit from a patent-assertion entity is about money. A suit involving a generic manufacturer that has filed an abbreviated new drug application (an ANDA, in the filing's language), or a biosimilar maker, or a direct competitor that already ships a rival product, is about market entry. In pharmaceuticals, the ANDA paragraph IV certification is the tell: the generic is telling the FDA the brand's patents are invalid or won't be infringed. That's not a negotiation over a license fee. That's a plan to take the customers.

2. Which patents are left after the compound patent expires

The patent doing the most work is usually the one on the molecule itself. Once it expires, the brand typically leans on later patents covering a dosing regimen, a formulation or a method of use. Those are narrower and easier to attack as obvious. When the business description shows the compound patent has expired or is about to, and the litigation section shows the company defending only secondary patents, the moat has already gone from a wall to a fence. It may hold. It's just a different kind of structure.

3. Inter partes review petitions and invalidity counterclaims

An inter partes review (IPR) is a challenge to a patent's validity filed with the Patent Trial and Appeal Board rather than a court. It's faster, the standard of proof is lower than in district court, and challengers have historically done well there. Companies usually disclose IPR petitions against material patents. When the same patent faces both an IPR and an invalidity counterclaim in court, the challenger is attacking on two fronts, and the brand has to win both.

4. Settlement terms that license rivals in

A settlement reads like good news because the uncertainty goes away. But read the terms. Many pharmaceutical settlements end with the brand granting the challenger a license to enter on a specific date, sometimes years before the last patent expires. Jazz Pharmaceuticals resolved its Xyrem litigation that way, with settlements that allowed authorized-generic entry beginning in 2023. A settlement like that doesn't defend the moat. It sets the date the moat ends, and you can usually find that date in the filing.

5. Language that shifts between filings

Compare this year's legal proceedings section and risk factors with last year's. Watch for a risk factor that moves from "could" to "will likely," a disclosure that adds the phrase "at risk" to describe a competitor's launch, or a contingency note that stops saying the company "intends to vigorously defend" and starts describing the appeal. Companies rarely announce that a moat is weakening. The change shows up as small edits to wording that otherwise repeats year to year, much like the patterns I described in five early warning signs a moat is eroding. It's the same habit that pays off when reading retention disclosures for lock-in: the risk factors confess more than the headline metrics do.

Vanda and HETLIOZ: A Moat Lost in Court

Vanda Pharmaceuticals is a useful worked example because the whole sequence played out in public filings over about eighteen months, and every one of the five signals appeared in order.

HETLIOZ (tasimelteon), Vanda's treatment for Non-24-Hour Sleep-Wake Disorder, was one of the company's two main commercial products. By late 2022 the compound patent had expired, and Vanda was defending its exclusivity with later patents on how the drug is dosed and used. Teva and Apotex had filed ANDAs to sell generic tasimelteon, and Vanda had sued them. That's signals one and two together: challengers who wanted to sell the same product, and a defense built on secondary patents.

On December 13, 2022, the U.S. District Court for the District of Delaware found the asserted claims of four Vanda patents (RE46,604; 9,730,910; 10,149,829; and 10,376,487) invalid as obvious. The Federal Circuit affirmed in May 2023 in a nonprecedential opinion. On April 22, 2024, the Supreme Court declined to hear Vanda's appeal (docket No. 23-768). Generic tasimelteon reached the market while the appeals were still pending, and Vanda's own disclosures described those launches as at risk. That's signal five: the wording changed before the litigation was formally over.

Now the financial statements. According to Vanda's 10-K for fiscal 2021, the company reported revenue of $268.7 million and operating income of $42.2 million. Its 10-K for fiscal 2022 shows revenue of $254.4 million and operating income of $6.3 million. Its 10-K for fiscal 2023 shows revenue of $192.6 million and an operating loss of $14.0 million. Working from those line items:

Operating margin = operating income ÷ revenue. Fiscal 2021: $42.2M ÷ $268.7M ≈ 15.7%. Fiscal 2023: –$14.0M ÷ $192.6M ≈ –7.2%. Revenue change, fiscal 2022 to 2023: ($192.6M – $254.4M) ÷ $254.4M ≈ –24%.

Those are company-wide figures, and HETLIOZ wasn't Vanda's only product, so not all of that decline belongs to one drug. But the order of events is the point. The legal proceedings section described the threat in 2022. The court ruled in December 2022. The full-year revenue effect showed up in fiscal 2023, and the move from operating profit to operating loss came with it. Someone reading only the income statement learned about the lost moat a year after someone reading Item 3 did.

Amarin's Vascepa followed a similar path. A Nevada district court invalidated key patents in March 2020, generics followed, and in June 2026 the Supreme Court ruled that Hikma's generic, sold with a label that carved out the patented use, did not infringe Amarin's patents. It's a different legal theory from Vanda's. The structural lesson is the same: once a franchise rests on method-of-use patents, the moat is a legal argument, and legal arguments can be lost. The same logic applies outside drugs, too: in moats in regulated industries I argued that any barrier granted by a rule can be taken away by one.

Where This Reading Goes Wrong

The method has limits, and I'll be honest about the biggest one. The disclosure tells you that a fight exists. It doesn't tell you who will win, and brands do win. A federal district court in Delaware ruled on September 30, 2026 that Liquidia's Yutrepia infringes valid claims of a United Therapeutics patent, which is the opposite result from Vanda's: the incumbent's patent held. Liquidia has said it will appeal. An investor who treated every challenge as a lost moat would have been wrong there, at least so far.

I'm also less sure than I'd like to be about how to weigh IPR petitions on their own. They're common enough that some companies treat them as routine, and a petition that the Board declines to institute means very little. The signal is much stronger once review is actually instituted against a patent that covers a material product.

Two other mistakes are worth naming. The first is treating litigation as a reason to dismiss the moat entirely, when a company with several protected products and a pipeline can lose one case and keep most of its competitive position. The second runs the other way: assuming a settlement is a win without reading the licensed entry date. Both come from reading the headline of the disclosure rather than the terms. And none of this replaces the work of checking whether a moat has other sources, such as manufacturing know-how, physician relationships or switching costs, that survive the patent. When the patent is the only thing standing, ask the blunt version of the question: what would it take to displace them? In a patent case, it may take only a court date.

Key Takeaways

• Most litigation in a 10-K is the routine cost of owning something worth copying. The suits that matter target the asset carrying the profits, come from challengers who want to sell a substitute, and would remove the barrier if lost.
• Read five things: who is suing and what they want to sell, which patents remain after the compound patent expires, IPR petitions and invalidity counterclaims, settlement terms that license rivals in, and wording that changes between filings.
• In Vanda's case the patents were invalidated in December 2022, and the company's 10-Ks show revenue falling from $254.4 million in fiscal 2022 to $192.6 million in fiscal 2023, with operating income turning to a loss. The litigation disclosures showed the problem a year before the income statement did.
• A disclosed challenge doesn't predict the outcome. Incumbents sometimes win, as United Therapeutics did at the district court in September 2026. Treat an active challenge to a franchise's last protective patents as a cap on the moat rating rather than a verdict.